Posted inBiotechnology
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.
Posted inBiotechnology
Amgen’s Horizon-acquired fusion protein eases Sjögren’s severity in ph. 3 win
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive…
Posted inBiotechnology
Vertex’s midstage data amplify kidney disease market opportunity
Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the…
Posted inBiotechnology
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich…
Posted inBiotechnology
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis drug candidate has hit its primary endpoint, positioning…
Posted inMedical Technology
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
Siemens Healthineers is joining forces with Novo to help boost awareness and diagnosis of fatty liver disease.
Posted inMedical Technology
Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device
The FDA gave the green light to a first and only sirolimus drug-eluting balloon designed by Cordis to treat coronary…
Posted inMedical Technology
Anaconda Biomed snares $56M in funding for endovascular tech
Medtech startup Anaconda Biomed has hauled in $53 million to help finish off work on a pivotal trial for its…
Posted inBiotechnology
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as…
Posted inBiotechnology
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up to go…